@ARTICLE{
author={Kulkarni R,Karim Abdul F,Glamocanin S,Janic Dragana M,Vdovin V,Ozelo M,Rageliene L,Carboni E,Laguna P,Dobaczewski G,Seremetis S,Lindblom A,Santagostino E},
year={2013},
title={Results from a large multinational clinical trial (guardian (TM) 3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics},
journal={HAEMOPHILIA},
volume={19},
number={5},
pages={698-705},
document_type={Article},
} 

@ARTICLE{
author={Serban M,Skotnicki AB,Colovic Milica D,Jinca C,Klukowska A,Laguna P,Wolf DM},
year={2012},
title={Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine (R) in previously treated patients with severe haemophilia B},
journal={HAEMOPHILIA},
volume={18},
number={2},
pages={175-181},
document_type={Article},
}